Alejandro Lopez Mas, MD
Interventional Cardiology · Ponce, PRNPI 1043487960
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,996 of the $142,184 with a category attached, or 78.8%. 25 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 42.2% of the total. Reporting peaked in 2019 at $35,416 and has fallen 80.2% since, to $7,003 in 2025. Among interventional cardiology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 608 payments — averaging $233.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$60K
- Pfizer Pharmaceuticals LLC$26K
- Boston Scientific$23K
- AstraZeneca$8K
- Pfizer$8K
- Edwards Lifesciences$5K
- plus $12K from 19 others
What the payments were for
- Consulting fees$5,0904%
- Speaking & faculty fees$111,99679%
- Travel & lodging$7,5735%
- Food & beverage$17,51512%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 77 | $60,014 |
| Pfizer Pharmaceuticals LLC | 18 | $25,780 |
| Boston Scientific | 110 | $23,203 |
| AstraZeneca | 28 | $8,308 |
| Pfizer | 4 | $7,648 |
| Edwards Lifesciences | 88 | $5,334 |
| Johnson & Johnson | 38 | $4,614 |
| Medtronic(2 entities) | 39 | $1,522 |
| Boehringer Ingelheim | 43 | $1,395 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 51 | $804 |
| Bayer | 9 | $732 |
| Abbott | 31 | $722 |
| Amgen | 13 | $664 |
| PBG Puerto Rico LLC | 26 | $509 |
| Bayer Puerto Rico Inc. | 9 | $234 |
| Scpharmaceuticals Inc. | 3 | $178 |
| Merck | 8 | $153 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Novartis | 5 | $88 |
| Abiomed | 1 | $78 |
| Johnson And Johnson International | 2 | $32 |
| Terumo Medical Corporation | 1 | $26 |
| Angiodynamics, Inc. | 1 | $23 |
| Cardinal Health P.r. 120 Inc | 1 | $13 |
| Cordis US CORP. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$90,514
- LOKELMA$7,575
- ROTAPRO$5,449
- SYNERGY$3,875
- XARELTO$3,640
- Rotablator Rotational Atherectomy System Console Kit$3,000
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,529
- GUIDEZILLA$2,000
- AVVIGO Guidance System$1,875
- FIGHTER$1,500
- WOLVERINE CORONARY CUTTING BALLOON$1,500
- COMET$1,200
- PASCAL$645
- Kerendia$604
- COREVALVE EVOLUT R$585
- JARDIANCE$474
- KRYSTEXXA$236
- WATCHMAN Access System$130
- FUROSCIX$125
- MitraClip$122
How this compares
$142,184 in reported general payments places this provider in the 90th percentile of 39 interventional cardiology providers in Puerto Rico.
See all interventional cardiology providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 749 | $595,175 |
| FarxigaDapagliflozin Propanediol | 595 | $433,942 |
| EntrestoSacubitril/Valsartan | 333 | $278,582 |
| EliquisApixaban | 290 | $217,872 |
| XareltoRivaroxaban | 150 | $97,234 |
| BrilintaTicagrelor | 99 | $52,364 |
| GlyxambiEmpagliflozin/Linagliptin | 57 | $36,466 |
| SynjardyEmpagliflozin/Metformin Hcl | 21 | $17,532 |
| TrulicityDulaglutide | 16 | $15,637 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 238 | $13,913 |
| Metoprolol Succinate | 785 | $11,061 |
| Repatha SureclickEvolocumab | 15 | $10,544 |
| Candesartan Cilexetil | 135 | $10,197 |
| Atorvastatin Calcium | 919 | $9,387 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $8,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Synjardy | $1,395 | $649,173827 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $8,308 | $495,227706 claims |
| NovartisEntresto | $88 | $278,582333 claims |
| PfizerEliquis | $7,648 | $217,872290 claims |
| Johnson & JohnsonXarelto | $4,614 | $97,234150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 interventional cardiology providers in Puerto Rico.
Other interventional cardiology in Ponce
- Enrique Hernandez VilaPonce$44K
- Cesar Cruz GarciaPonce$14K
- Rafael RiveraPonce$11K
- Jorge Jovane JaramilloPonce$3K
- Emilio del Toro AgrelotPonce$708
- Damian Grovas AbadSan Juan$498K
- Eric Carro JimenezSan Juan$416K
- Hector Martinez GonzalezMayaguez$261K
- Ricardo SantiagoManati$131K
- Edwin I Perez MarreroSan Juan$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.